» Articles » PMID: 38772406

Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs

Overview
Journal Semin Liver Dis
Publisher Thieme
Specialty Gastroenterology
Date 2024 May 21
PMID 38772406
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic porphyrias are a group of metabolic disorders that are characterized by overproduction and accumulation of porphyrin precursors in the liver. These porphyrins cause neurologic symptoms as well as cutaneous photosensitivity, and in some cases patients can experience life-threatening acute neurovisceral attacks. This review describes the acute hepatic porphyrias in detail, including acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria, as well as the hepatic porphyrias with cutaneous manifestations such as porphyria cutanea tarda and hepatoerythropoietic porphyria. Each section will cover disease prevalence, clinical manifestations, and current therapies, including strategies to manage symptoms. Finally, we review new and emerging treatment modalities, including gene therapy through use of adeno-associated vectors and chaperone therapies such as lipid nanoparticle and small interfering RNA-based therapeutics.

Citing Articles

Practical Recommendations in the Treatment of Acute and Chronic Life-Threatening Infectious Diseases in Patients with Acute Hepatic Porphyria.

Badia B, Serrano P, Barile J, Seneor D, Mendes P, Cavalheiro R Metabolites. 2025; 15(2).

PMID: 39997724 PMC: 11857646. DOI: 10.3390/metabo15020099.

References
1.
Jerico D, Luis E, Cusso L, Fernandez-Seara M, Morales X, Cordoba K . Brain ventricular enlargement in human and murine acute intermittent porphyria. Hum Mol Genet. 2020; 29(19):3211-3223. DOI: 10.1093/hmg/ddaa204. View

2.
Anderson K, Bloomer J, Bonkovsky H, Kushner J, Pierach C, Pimstone N . Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005; 142(6):439-50. DOI: 10.7326/0003-4819-142-6-200503150-00010. View

3.
Russell J, Monga S . Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. Annu Rev Pathol. 2017; 13:351-378. PMC: 5927358. DOI: 10.1146/annurev-pathol-020117-044010. View

4.
Towns C, Balakrishnan S, Florkowski C, Davies A, Barrington-Ward E . High penetrance, recurrent attacks and thrombus formation in a family with hereditary coproporphyria. JIMD Rep. 2022; 63(3):211-215. PMC: 8995837. DOI: 10.1002/jmd2.12281. View

5.
Akagi R, Kato N, Inoue R, Anderson K, Jaffe E, Sassa S . delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab. 2005; 87(4):329-36. DOI: 10.1016/j.ymgme.2005.10.011. View